Inventiva (IVA) completed the enrollment in a phase 3 clinical trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, a liver disease.

Enrollment targets were exceeded with 1,009 patients in the main cohort and 410 patients in the exploratory cohort, the company said Tuesday in a statement.

Completion of enrollment in the study before April 30 triggers the potential 116 million euros ($125.2 million) funding tranche of a structured financing of up to 348 million euros, Inventiva added.

Topline results of the study are expected in H2 2026.